Dimerix Opens Pediatric Site for Kidney Disease Trial; Shares Climb 4%
Dimerix (ASX:DXB) opened a pediatric site in Mexico for its ongoing phase three trial investigating the use of DMX-200 in patients with focal segmental glomerulosclerosis, a form of kidney disease, according to a Thursday filing with the Australian bourse.
The trial site is now ready to recruit patients ages 12 to 17 who will be given the same dose as adults, the biopharmaceutical firm said in the filing. An additional 14 pediatric sites will be opened in the US, the UK, and Argentina.
An interim analysis for the trial is set for release in the middle of 2025, per the filing.
Dimerix's shares climbed almost 4% in recent Thursday trade.
Price (AUD): $0.41, Change: $+0.015, Percent Change: +3.85%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。